文献速递新发突发、热带与寄生虫病

乌干达孕妇重复每月双氢青蒿素-哌喹给药后哌喹诱导的QTc延长减轻

Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
PubMed 文献 · Clin Infect Dis · 2022-01-01

基于一项随机对照试验,乌干达孕妇在妊娠中晚期每月接受双氢青蒿素-哌喹(DHA-PQ)或磺胺多辛-乙胺嘧啶(SP)预防疟疾。哌喹浓度与Fridericia校正QTc呈正线性关系,该关系在妊娠20、28、36周逐渐减弱;61%的孕妇36周QTc变化小于20周;9例DHA-PQ组发生3-4级心脏不良事件;SP与QTc变化无关。结论认为重复每月DHA-PQ给药未增加QTc延长风险。

要点

  • 哌喹浓度每增加100 ng/mL,QTc在妊娠20、28、36周分别延长4.42、3.28、2.13毫秒,呈递减趋势。
  • 61%(n=183)的孕妇36周QTc变化小于20周,提示重复给药未导致QTc进行性延长。
  • DHA-PQ组9例发生3-4级心脏不良事件;SP与QTc变化无关。

核心结论

  • 重复每月DHA-PQ给药未导致QTc延长风险增加,且给药后QTc间期逐渐缩短;孕妇每月DHA-PQ给药的QTc延长风险极小。

研究设计与样本

  • 数据来自一项随机对照试验,孕妇在妊娠中晚期每月接受DHA-PQ(120/960 mg;n=373)或SP(1500/75 mg;n=375)预防疟疾。
  • 每月采集哌喹谷浓度样本,并在妊娠20、28、36周记录给药前和给药后心电图;采用非线性混合效应模型评估哌喹药代动力学-QTc关系及SP对QTc的影响。

主要发现

  • 哌喹浓度与Fridericia校正QTc间期呈正线性关系,妊娠20、28、36周哌喹浓度每增加100 ng/mL,QTc分别延长4.42、3.28、2.13毫秒。
  • 61%(n=183)的孕妇36周QTc变化小于20周。
  • DHA-PQ组9例发生3-4级心脏不良事件;SP与QTc变化无关。

关键数值与推荐

  • DHA-PQ剂量为120/960 mg DHA/PQ,每月给药;SP剂量为1500/75 mg。
  • 哌喹浓度每增加100 ng/mL,QTc延长在妊娠20、28、36周分别为4.42、3.28、2.13毫秒。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intermittent preventive treatment with monthly dihydroartemisinin-piperaquine (DHA-PQ) is highly effective at preventing both malaria during pregnancy and placental malaria. Piperaquine prolongs the corrected QT interval (QTc), and it is possible that repeated monthly dosing could lead to progressive QTc prolongation. Intensive characterization of the relationship between piperaquine concentration and QTc interval throughout pregnancy can inform effective, safe prevention guidelines. METHODS: Data were collected from a randomized controlled trial, where pregnant Ugandan women received malaria chemoprevention with monthly DHA-PQ (120/960 mg DHA/PQ; n = 373) or sulfadoxine-pyrimethamine (SP; 1500/75 mg; n = 375) during the second and third trimesters of pregnancy. Monthly trough piperaquine samples were collected throughout pregnancy, and pre- and postdose electrocardiograms were recorded at 20, 28, and 36 weeks' gestation in each woman. The pharmacokinetics-QTc relationship for piperaquine and QTc for SP were assessed using nonlinear mixed-effects modeling. RESULTS: A positive linear relationship between piperaquine concentration and Fridericia corrected QTc interval was identified. This relationship progressively decreased from a 4.42 to 3.28 to 2.13 millisecond increase per 100 ng/mL increase in piperaquine concentration at 20, 28, and 36 weeks' gestation, respectively. Furthermore, 61% (n = 183) of women had a smaller change in QTc at week 36 than week 20. Nine women given DHA-PQ had grade 3-4 cardiac adverse events. SP was not associated with any change in QTc. CONCLUSIONS: Repeated DHA-PQ dosing did not result in increased risk of QTc prolongation and the postdose QTc intervals progressively decreased. Monthly dosing of DHA-PQ in pregnant women carries minimal risk of QTc prolongation. CLINICAL TRIALS REGISTRATION: NCT02793622.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hughes E, Wallender E, Kajubi R, et al. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. Clin Infect Dis. 2022. PMID: 34864925. doi:10.1093/cid/ciab965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。